PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15502112-3 2005 We hypothesized that in patients receiving low maintenance dose budesonide/formoterol (bud/form), replacing short-acting beta2-agonist (SABA) reliever with as-needed bud/form would provide rapid symptom relief and simultaneous adjustment in antiinflammatory therapy, thereby reducing exacerbations. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 136-140 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 121-126 29332144-8 2018 Biological plausibility of the deleterious effects of beta2-agonists (S)-enantiomers is provided by in vitro and in vivo studies from the short-acting beta2-agonist (SABA) salbutamol. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 166-170 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 54-59 34734512-1 2021 Short-acting beta2-agonist (SABA) use is known to be lower in Korean patients with asthma than in those from other countries, while the rate of asthma exacerbations in Korea is higher than in other countries. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 28-32 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-18 14626340-1 2003 STUDY OBJECTIVES: Assess compliance to asthma guidelines and influence of age concerning inhaled short-acting beta2-agonist (SABA) utilization in 5 to 45-year-old asthmatic subjects in the province of Quebec. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 125-129 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 110-115 30907188-9 2020 Abbreviations AIR Anti-Inflammatory Reliever Therapy DMAADs disease modifying anti-asthmatic drugs GINA Global initiative for asthma ICS Inhaled corticosteroids LABA Long acting beta2 agonists LAMA Long acting muscarinic antagonists PICO population, intervention, comparator, and outcomes PRN pro re nata RA rheumatoid arthritis SABA Short acting beta2 agonists TTT Treat to target. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 329-333 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 178-183 30907188-9 2020 Abbreviations AIR Anti-Inflammatory Reliever Therapy DMAADs disease modifying anti-asthmatic drugs GINA Global initiative for asthma ICS Inhaled corticosteroids LABA Long acting beta2 agonists LAMA Long acting muscarinic antagonists PICO population, intervention, comparator, and outcomes PRN pro re nata RA rheumatoid arthritis SABA Short acting beta2 agonists TTT Treat to target. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 329-333 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 347-352 30297688-1 2018 BACKGROUND Asthma is a common disease in the U.S. POPULATION: Initial therapy in the stepwise approach for asthma management is short-acting beta2-agonist (SABA) therapy as needed for symptom control. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 156-160 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 141-146 29806185-1 2018 PURPOSE: Use electronic health record (EHR) data to (1) estimate the risk of arrhythmia associated with inhaled short-acting beta-2 agonists (SABA) in pediatric patients and (2) determine whether risk varied by on-label versus off-label prescribing. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 142-146 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 125-131 29332144-8 2018 Biological plausibility of the deleterious effects of beta2-agonists (S)-enantiomers is provided by in vitro and in vivo studies from the short-acting beta2-agonist (SABA) salbutamol. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 166-170 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 151-156 23860295-3 2014 OBJECTIVE: To evaluate the effects of a short-acting beta2-agonist (SABA) on the regional distribution of lung sounds in COPD patients. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 68-72 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 53-58 29429262-7 2018 85.7% (3 277/3 823) of the patients had right perception on the condition of using short-acting beta2-agonists (SABA). 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 112-116 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 96-101 27582089-6 2016 ICSs are currently recommended as "preventer" therapy for patients who use a "reliever" medication (e.g. short-acting beta2 agonist (SABA), salbutamol) three or more times per week. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 133-137 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 118-123 25840499-1 2015 BACKGROUND: One goal of guideline-based asthma therapy is minimal use of short-acting beta2 agonist (SABA) medications. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 101-105 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 86-91 25130680-1 2014 BACKGROUND: A simple rule based on short-acting inhaled beta2-agonist (SABA) use could identify patients with chronic obstructive pulmonary disease (COPD) at increased risk of exacerbations and signal the need for maintenance therapy change, similar to asthma "Rules of Two( )". 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 71-75 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 56-61 24360293-1 2014 BACKGROUND: Short and long-acting beta2-agonists (SABA and LABA) have a crucial role in asthma management during pregnancy, as stated in the current guidelines. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 50-54 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 34-39 24360293-8 2014 One study reported a significant increased risk of congenital malformations with LABA and four studies reported a significant increased risk of congenital malformations with beta2-agonists (SABA and/or LABA). 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 190-194 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 174-179 29535158-3 2018 OBJECTIVES: We assessed the role of air pollution exposure for increased short-acting beta-2-agonist (SABA) use in patients with COPD through use of remote monitoring technology. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 102-106 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 86-92 26293575-2 2015 We hypothesized that short-acting beta2-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 49-53 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 34-39 25213370-2 2015 High-dose, frequent or continuous nebulized short-acting beta2 agonist (SABA) therapy that can be combined with a short-acting muscarinic antagonist (SAMA) is the backbone of treatment. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 72-76 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 57-62 25574908-10 2015 Although ICS and short-acting beta2 agonist (SABA) for rescue treatment can be obtained to a certain extent by using separate ICS and SABA inhalers, the first step is to ensure access to affordable, quality-assured essential asthma medicine in resource-limited settings. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 45-49 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 30-35 25574908-10 2015 Although ICS and short-acting beta2 agonist (SABA) for rescue treatment can be obtained to a certain extent by using separate ICS and SABA inhalers, the first step is to ensure access to affordable, quality-assured essential asthma medicine in resource-limited settings. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 134-138 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 30-35 25017534-1 2014 BACKGROUND: Excessive use of short-acting beta2-agonists (SABA) indicates impaired asthma control. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 58-62 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 42-47 21948561-2 2011 Short-acting beta2-agonists (SABA) are frequently used as rescue medications and long-acting beta2-agonists (LABA) are used as add-on controller therapy for asthma during pregnancy. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 29-33 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-18 24089311-18 2013 AUTHORS" CONCLUSIONS: Evidence of low to moderate quality shows that beta2-agonists, both SABA and LABA, when administered in a single dose, are effective and safe in preventing EIA.Long-term regular administration of inhaled beta2-agonists induces tolerance and lacks sufficient safety data. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 90-94 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 69-74 24089311-18 2013 AUTHORS" CONCLUSIONS: Evidence of low to moderate quality shows that beta2-agonists, both SABA and LABA, when administered in a single dose, are effective and safe in preventing EIA.Long-term regular administration of inhaled beta2-agonists induces tolerance and lacks sufficient safety data. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 90-94 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 226-231 22849986-19 2012 An increasing association between uncontrolled asthma and an increasing annual quantity of inhaled short-acting beta-2-agonists (SABA) usage was demonstrated. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 129-133 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 112-118 22824566-8 2012 In school-aged children, 50% were initiated on inhaled short-acting bronchodilating beta2-agonists (SABA) in monotherapy. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 100-104 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 84-89 24236741-7 2013 The current recommended treatment approach to managing an acute asthma exacerbation is to administer a short-acting inhaled beta2-agonist (SABA). 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 139-143 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 124-129 22816878-2 2012 One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA), supplemented by a short-acting beta2-agonist (SABA) as needed. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 184-188 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 169-174 22097692-1 2011 Bronchodilatation is preferably achieved with beta-2-agonists (SABA), salbutamol. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 63-67 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 46-52 20391960-6 2010 The principal goals of managing an asthma acute exacerbation may be summarized as maintenance of adequate arterial oxygen saturation with supplemental oxygen, relief of airflow obstruction with repetitive administration of short acting beta-2 agonists (SABA), and treatment of airway inflammation with systemic corticosteroids (CS) to prevent future relapses. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 253-257 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 236-242 21740399-3 2011 Both short acting and long acting beta-2 agonists (SABA and LABA) are of particular importance among the bronchodilators used in asthma. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 51-55 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 34-40 20491347-3 2010 Bronchodilatator medications, including SABA (slow acting beta-2 agonists) and LABA (long acting beta-2 agonists) are central to the symptomatic management of COPD. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 40-44 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 58-64 16625543-2 2006 Patients often report symptomatic improvement with short-acting beta-2 agonists (SABA) and anticholinergic bronchodilator medications, and both are recommended in COPD guidelines. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 81-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 64-70 19206182-4 2009 We propose, therefore, that after an initial period of stabilization with age-appropriate doses of oral glucocorticoids or high-dose ICS and short-acting beta-2 agonists (SABA), caretakers can stop treatment once there are no longer signs or symptoms of asthma. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 171-175 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 154-160 18430791-3 2008 After extubation, she reported multiple hospitalizations for asthma with one prior intubation, adherence to asthma medications, and very frequent use of her short-acting beta(2)-agonist (SABA). 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 187-191 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 170-176 19032229-2 2008 For patients with moderate to severe asthma an inhaled corticosteroid (ICS) or an ICS/long-acting beta2-agonist (LABA) combination with a short-acting beta2-agonist (SABA) as reliever is recommended. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 166-170 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 151-156 16371219-8 2005 Most (90.4%) of the pediatricians would use a short-acting beta2 agonist (SABA) via a metered-dose inhaler with a spacer and a face mask or nebulizer. 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole 74-78 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 59-64